

VIA FACSIMILE TRANSMISSION

Date of Deposit: January 16, 2002

Attorney Docket No. 22058-521

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Keith et al.

SERIAL NUMBER: 09/521,696

EXAMINER: J. Seharaseyon

FILING DATE: March 9, 2000

ART UNIT: 1647

FOR: Use of Interleukin-11 To Prevent Immune-Mediated Cytotoxicity

Assistant Commissioner for Patents  
Washington, DC 20231

## TRANSMITTAL LETTER

Transmitted herewith for filing in the above-referenced patent application are the following documents:


1. Supplemental Response (4 pgs); and,
2. Certificate of Transmission (1 pg).

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts.

The Commissioner is hereby authorized to charge payment of any additional fees required in connection with the papers transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0311 (Reference No. 22058-521).

Date: January 16, 2002

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529

David E. Johnson, Reg. No. 41,874

Attorneys for Applicants

MINTZ, LEVIN, COHN, FERRIS,

GLOVSKY and POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

PTO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the  
United States Patent and Trademark Office

on January 16, 2002  
Date

Marie Sulkey  
Signature

MARIE SULKEY  
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

MINTZ LEVIN  
COHN FERRIS  
GLOVSKY AND  
POPEO PC

Boston  
New York  
Reston  
Washington

One Financial Center  
Boston, Massachusetts 02111  
617 542 6000  
617 542 2241 fax  
www.mintz.com

**OFFICIAL**

**FAX RECEIVED**

JAN 17 2001

**GROUP 1600**

# *Fax Cover Sheet*

**DATE:** January 16, 2002

**FROM:** David E. Johnson, Ph.D., J.D.  
Direct Dial 617 348 1768  
[dejohnson@mintz.com](mailto:dejohnson@mintz.com)

**To:**

NAME	BUSINESS #	FAX #
J. Seharaseyon, Examiner U.S. Patent and Trademark Office	703-305-1112	703-305-7461 305-3592

**RE:**

US Patent Application No. 09/521,696  
"Use of Interleukin-11 To Prevent Immune-Mediated Cytotoxicity"  
Genetics Institute Reference: GI5345  
Our Reference: 22058-521

308-2742  
305-1935

**We are sending a total of 7 pages, including this cover sheet.**

Please call us at 617 654 8024, if you experience any problems.

## STATEMENT OF CONFIDENTIALITY

THE INFORMATION CONTAINED IN THIS FAX IS INTENDED FOR THE EXCLUSIVE USE OF THE ADDRESSEE AND MAY CONTAIN CONFIDENTIAL OR PRIVILEGED INFORMATION. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY FORM OR DISSEMINATION OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF THIS FAX WAS SENT IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY PHONE.

TRA 1618997v